|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Arrowhead Pharmaceuticals
|
2023 | |||
Arrowhead Pharmaceuticals fiscal Q2 2023 |
|||
May 2, 2023 | |||
2022 | |||
Arrowhead Pharmaceuticals fiscal Q2 2022 |
Arrowhead Pharmaceuticals fiscal Q3 2022 |
Arrowhead Pharmaceuticals fiscal Q4 2022 |
Arrowhead Pharmaceuticals fiscal Q1 2023 |
May 10, 2022 | Aug. 4, 2022 | Nov. 28, 2022 | Feb. 6, 2023 |
2021 | |||
Arrowhead Pharmaceuticals fiscal Q2 2021 |
Arrowhead Pharmaceuticals fiscal Q3 2021 |
Arrowhead Pharmaceuticals fiscal Q4 2021 |
Arrowhead Pharmaceuticals fiscal Q1 2022 |
May 4, 2021 | Aug. 5, 2021 | Nov. 22, 2021 | Feb. 2, 2022 |
2020 | |||
Arrowhead Pharmaceuticals fiscal Q2 2020 |
Arrowhead Pharmaceuticals fiscal Q3 2020 |
Arrowhead Pharmaceuticals fiscal Q4 2020 |
Arrowhead Pharmaceuticals fiscal Q1 2021 |
May 7, 2020 | Aug. 5, 2020 | Nov. 23, 2020 | Feb. 4, 2021 |
2019 | |||
Arrowhead Pharmaceuticals fiscal Q3 2019 |
Arrowhead Pharmaceuticals fiscal Q4 2019 |
Arrowhead Pharmaceuticals fiscal Q1 2020 |
|
na | August 5, 2019 | Nov. 25, 2019 | Feb. 5, 2020 |
Arrowhead Pharmaceuticals (ARWR) is a clinical-stage biotechnology company specializing in RNAi therapies for genetic diseases.
Arrowhead Pharmaceutical web site
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
AMAT |
AMGN |
APRE |
BIIB |
BMY |
CDTX |
CLDX |
FATE |
GILD |
GLYC |
ILMN |
INO |
IONS |
MCHP |
MRNA |
PLX |
REGN |
RNA |
SAGE |
SANA |
SGEN |
SYRS |
VBLT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers